drugset / Trial / NCT04066530

A Study to Evaluate the Efficacy and Safety of AD-203

NCT04066530

Phase 3 Completed 475 enrolled Addpharma Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicenter, active-controlled , randomized, double-blinded, paralleled group clinical study to evaluate the efficacy and safety of AD-203 to demonstrate the non-inferiority of AD-203 compared with Mucosta tab. in patients with acute or chronic gastritis

Timeline

Start
2019-09-23
Primary completion
2020-02-26
Completion
2020-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-203 Unknown
Comparator Rebamipide Small molecule

Indications